Make FDA Advisory Committee Votes Binding Unless the Commissioner Provides Written Evidence-Based Justification
Description
Amend the Federal Food, Drug, and Cosmetic Act to require that when the FDA overrides an advisory committee recommendation, the Commissioner must publish a written justification specifically addressing the scientific objections raised by the committee, with that justification subject to independent scientific review within 90 days.
The aducanumab case — 10-0-1 committee vote against, FDA approved — is only the most visible instance of a structural problem. Advisory committees are convened precisely because FDA staff cannot maintain deep expertise across every therapeutic area.
When the agency can override their recommendation with a general reference to its own judgment, the committees serve a theatrical function rather than a scientific one. Three committee members resigned over aducanumab. That level of professional protest from academics who have nothing to gain from the controversy deserves a structural response, not a press release.
Implementation Pathway
Required Resources
Impact Overview
Overall net impact: +5.00
Net Score by Horizon
Benefits vs Harms Count
- Benefits
- Harms
Impact Analysis
Overall Net Impact
Combined analysis across all timeframes
Short-term
0-2 years
- Immediate increase in public and scientific trust in the FDA's decision-making process for high-stakes drug approvals.
- Increased accountability for agency leadership regarding controversial drug approvals like Aduhelm or Leqembi.
- Potential bottlenecking of urgent drug approval timelines due to mandatory 90-day review requirements.
- Administrative burden on FDA staff to document and justify internal disagreements during active review cycles.
Mid-term
3-10 years
- Higher quality scientific discourse resulting from the requirement to publicly address specific technical objections.
- Reduction in potential regulatory capture as the agency must defend itself against independent academic peer review.
- Increased participation by top-tier academic experts in advisory committees, knowing their input carries structural weight.
- Potential for politicized scientific peer review panels to become a secondary venue for industry lobbying or ideological disputes.
Long-term
10+ years
- Enhanced institutional credibility for the FDA as an evidence-driven rather than policy-driven organization.
- More robust and predictable drug development pipelines resulting from clearer adherence to consensus scientific standards.
- Long-term stability in regulatory processes that withstand shifts in political administration.
- Risk of 'regulatory conservatism' where the FDA becomes overly cautious and slow to approve breakthrough therapies to avoid public justification battles.
- FDA commissioners may become more selective in convening advisory committees to avoid the administrative burden of forced justifications.
- Potential for the independent scientific review board to develop its own biases, effectively creating a 'shadow regulator' with no legislative accountability.
- A chilling effect on internal FDA debate where staff might suppress dissenting views early in the process to avoid triggering a public justification requirement.